


Reducing recurrent stroke in cryptogenic stroke patients


Patent foramen ovale (PFO) closure patient selection educational guide

Step 1: Tissue diagnosis




AFIB	Atrial fibrillation
CT	Computed tomography
CTA	Computed tomography angiography
DVT	Deep vein thrombosis
FLAIR	Fluid-attenuated inversion recovery
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
PE	Pulmonary embolism
RCVS	Reversible cerebral vasoconstriction syndrome
TCD	Transcranial doppler
TEE	Transesophageal echocardiography
TTE	Transthoracic echocardiogram

Step 2: Vessel imaging



Step 3: Emboli workup



Used with permission from John J. Volpi, MD, BA Neurology Houston Methodist Hospital. This algorithm represents Dr. Volpi's general clinical practice.

All content about medical diagnosis and treatment is for general information purposes only. This information is not intended or implied to be a substitute for professional medical diagnosis, treatment or care. Every medical situation is unique to the patient and requires appropriate clinical judgment from a qualified physician.

* The Gore REDUCE Clinical Study did not include patients on anticoagulants. The REDUCE study determined safety and efficacy of patent foramen ovale (PFO) closure with the GORE® CARDIOFORM® Septal Occluder or GORE® HELEX® Septal Occluder plus antiplatelet medical management compared to antiplatelet medical management alone in patients with a PFO and history of cryptogenic stroke. All PFO anatomies were incorporated into this study within indicated sizing parameters of the *Instructions for Use*.

** Refer to *Instructions for Use*.

Duration of anticoagulant use varies by case, and the decision to maintain its use in conjunction with PFO closure should be at the physician's discretion.



W. L. GORE & ASSOCIATES, INC.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific) 800.437.8181 (United States)
00800.6334.4673 (Europe) 928.779.2771 (United States)

goremedical.com

INDICATIONS FOR USE outside of U.S.: The GORE® CARDIOFORM Septal Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of atrial septal defects (ASDs), such as ostium secundum and patent foramen ovale.

INDICATIONS FOR USE in the U.S.: The GORE® CARDIOFORM Septal Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of the following defects of the atrial septum: ostium secundum atrial septal defects (ASDs); patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke. **CONTRAINDICATIONS:** The GORE® CARDIOFORM Septal Occluder is contraindicated for use in patients: unable to take antiplatelet or anticoagulant medications such as aspirin, heparin, or warfarin; with anatomy where the GORE® CARDIOFORM Septal Occluder size or position would interfere with other intracardiac or intravascular structures, such as cardiac valves or pulmonary veins; with active endocarditis, or other infections producing bacteremia, or patients with known sepsis within one month of planned implantation, or any other infection that cannot be treated successfully prior to device placement; with known intracardiac thrombi. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and adverse events. Only

This information is intended for education and awareness only. Patients should consult their physician for information on the risks associated with the devices and surgical procedures discussed in this document. All surgical procedures carry potential health risks. Not all patients will be candidates for treatment with these devices, and individual outcomes may vary.

Products listed may not be available in all markets.

GORE®, CARDIOFORM®, HELEX®, and designs are trademarks of W. L. Gore & Associates.
© 2019 W. L. Gore & Associates, Inc. AX1564-EN3 JANUARY 2019

Consult Instructions for Use